[Clinical features and prognosis of mucosa-associated lymphoid tissue lymphoma].

Zhonghua Yi Xue Za Zhi

Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education); Department of Lymphoma, Peking University School of Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China. Email:

Published: March 2014

Objective: To explore the clinical features and treatments of mucosa-associated lymphoid tissue (MALT) lymphoma.

Methods: The clinical data of 80 MALT lymphoma patients treated from September 2000 to November 2012 were retrospectively analyzed.

Results: Among them, 32 (40.0%) had gastric MALT lymphoma and 48(60.0%) non-gastric MALT lymphoma. Gastric lymphoma associated anemia accounted for 50.0% (16/32) (25.0% (12/48) in non-gastric group, P = 0.022). In non-gastric group, stage III-IV diseases accounted for 35.4% (17/48) (12.5% (4/32) in gastric group, P = 0.022). During a median follow-up of 30 months, the 5-year overall survival (OS) rate was 90.0% and 5-year progression-free survival (PFS) rate 67.0%. For the non-gastric group, surgery plus chemotherapy group was superior in PFS to surgery alone group (the 3-year PFS rate 83.0% and 33.0%; median PFS 43.4 months and 20.3 months) (P = 0.040). Five-year OS in patients on first-line rituximab and chemotherapy without rituximab were 100.0% and 86.0% respectively (P = 0.106). Short-term response (OR = 0.258, P = 0.020) and low albumin (OR = 3.967, P = 0.009) were independent factor for PFS.

Conclusions: Non-gastric MALT lymphoma is easily disseminated. Systemic treatment may be considered for advanced non-gastric MALT lymphoma. Surgery often leaves residual lesions for gastric MALT lymphoma.

Download full-text PDF

Source

Publication Analysis

Top Keywords

malt lymphoma
24
non-gastric malt
12
non-gastric group
12
mucosa-associated lymphoid
8
lymphoid tissue
8
gastric malt
8
group 0022
8
pfs rate
8
malt
7
lymphoma
7

Similar Publications

Primary head and neck mucosa-associated lymphoid tissue lymphoma (HN-MALT) is a rare lymphoma with unknown incidence and prognosis. We allocated HN-MALT data from the Self-Surveillance, Epidemiology, and End Results database (2000-2021) into training and validation cohorts at a 7:3 ratio. A joinpoint regression analysis was used to examine sex-specific and age-group morbidities, and independent prognostic factors were identified through multivariate Cox analysis to construct a nomogram prediction model and verify the accuracy of prediction.

View Article and Find Full Text PDF

Primary Pulmonary MALT Lymphoma on 18F-FDG and 68Ga-FAPI PET/CT.

Clin Nucl Med

January 2025

From the Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Primary pulmonary mucosa-associated lymphoid tissue lymphoma is extremely rare. We present the 18F-FDG and 68Ga-FAPI PET/CT findings in a 56-year-old woman with pathologically confirmed primary pulmonary mucosa-associated lymphoid tissue lymphoma. 68Ga-FAPI PET/CT showed a higher uptake value than 18F-FDG PET/CT in the pulmonary lesion.

View Article and Find Full Text PDF

Clinical analysis of pulmonary mucosa-associated lymphoid tissue lymphoma coexisting with lung cancer.

BMC Cancer

January 2025

Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.

Background: Primary pulmonary Mucosa-associated lymphoid tissue (MALT) lymphoma is a sporadic disease with a favorable prognosis. Particularly, pulmonary MALT lymphoma coexisting with lung cancer is not only rare but also prone to misdiagnosis. The clinical characteristics and prognostic factors of this co-occurrence, however, remain poorly understood.

View Article and Find Full Text PDF

[Patient with diffuse large B-cell lymphoma: a good example of network in care.].

Recenti Prog Med

January 2025

UO Ematologia, Ospedale San Bortolo, Vicenza.

Chimeric Antigen Receptor T cell (CAR-T) therapy has revolutionized prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Success of CAR-T treatment heavily relies on early referral to the CAR-T center, on a short time of infusion of CAR-T cells from the lymphocyte collection and on a reduced burden of disease. Here we describe the case of a patient with diagnosis of High-grade B-cell lymphoma with MYC and BCL6 rearrangements, transformed from marginal zone lymphoma, referred with a refractory and rapidly progressive disease.

View Article and Find Full Text PDF

A 61-year-old male presented with hematemesis and melena. Biopsy and immunohistochemistry confirmed mucosa-associated lymphoid tissue (MALT) lymphoma in the posterior wall of the gastric antrum, prompting further evaluation with F-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT). In addition to elevated uptake in the gastric antrum, F-FDG PET/CT showed diffuse uptake in multiple bone marrow, initially suspected to indicate bone marrow involvement by lymphoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!